Application of image fusion biopsy based on PSMA PET in prostate cancer
10.3760/cma.j.cn112330-20210803-00410
- VernacularTitle:基于PSMA PET影像融合穿刺在前列腺癌诊断中的应用
- Author:
Qi HUANG
1
;
Zhibin KE
;
Ning XU
Author Information
1. 福建医科大学附属第一医院泌尿外科 福建医科大学泌尿外科研究所，福州 350005
- Keywords:
Prostate neoplasms;
Prostate specific membrane antigen;
Positron emission tomography/computed tomography;
Magnetic resonance imaging;
Prostate biopsy
- From:
Chinese Journal of Urology
2022;43(4):317-320
- CountryChina
- Language:Chinese
-
Abstract:
Prostate biopsy is the gold standard for diagnosis of prostate cancer. Positron emission tomography (PET) of prostate-specific membrane antigen is a new imaging technology, which has high clinical value in the detection of Clinically Significant Prostate Cancer. It also has high recognition ability for local recurrence and lymph node metastasis. Targeted prostate biopsy guided by PSMA PET can improve the detection rate of clinically significant prostate cancer, help guide the selection of prostate cancer bone biopsy lesions, plan the needle path, and improve the success rate of bone biopsy in patients with mCRPC. However, prospective randomized controlled studies are still needed to explore the feasibility of PSMA PET in targeted biopsy of prostate cancer.
